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Introduction {#sec001}
============

Globally, mosquito-borne diseases are a major health burden. To decrease mosquito populations, control programs often use integrated vector management practices including adulticide and larvicide application, source reduction, and biological control \[[@pntd.0006050.ref001]\]. However, these mosquito control methods are losing efficacy due to increasing insecticide resistance and changes in mosquito behavior \[[@pntd.0006050.ref002]--[@pntd.0006050.ref004]\]. With these concerns, novel and sustainable control methods are under investigation, including strategies that target the pathogen \[[@pntd.0006050.ref005],[@pntd.0006050.ref006]\]. *Wolbachia* is a maternally-inherited endosymbiotic bacterium that infects a large number of insects and other invertebrates \[[@pntd.0006050.ref007]\]. Infection by *Wolbachia* can cause broad effects on host physiology. For example, natural *Wolbachia* infections in fruit flies protect against pathogen-induced mortality \[[@pntd.0006050.ref008],[@pntd.0006050.ref009]\]. When experimentally transferred to uninfected mosquitoes, *Wolbachia* can suppress infection or transmission of viruses, *Plasmodium* parasites, and filarial nematodes \[[@pntd.0006050.ref010]--[@pntd.0006050.ref013]\]. *Wolbachia* also manipulates host reproduction in ways that allow it to spread through and persist in insect populations \[[@pntd.0006050.ref014]\].

Investigations using *Wolbachia*-infected mosquitoes as a control method for dengue virus are underway \[[@pntd.0006050.ref015]\], and field trials in Australia have indicated that *Wolbachia* can spread to near-fixation in naturally uninfected populations of *Aedes aegypti* mosquitoes \[[@pntd.0006050.ref016],[@pntd.0006050.ref017]\]. These *Wolbachia-*infected *Ae*. *aegypti* populations can persist years after release, and mosquitoes retain the dengue virus-blocking phenotype \[[@pntd.0006050.ref018]\]. Similar field experiments are being conducted in several other countries, but not all have reported successful replacement of the uninfected population with *Wolbachia*-infected mosquitoes \[[@pntd.0006050.ref019]\].

The effects of *Wolbachia*-induced pathogen interference may differ depending on mosquito species, *Wolbachia* strain, pathogen type, and environment conditions \[[@pntd.0006050.ref020]--[@pntd.0006050.ref022]\]. For example, in *Anopheles gambiae*, transient somatic infection of the *Wolbachia* strain *w*AlbB inhibits *Plasmodium falciparum* but enhances *Plasmodium berghei* parasites \[[@pntd.0006050.ref022],[@pntd.0006050.ref023]\]. Enhancement phenotypes have been observed in *Anopheles*, *Culex*, and *Aedes* mosquitoes, and across several malaria species and virus families \[[@pntd.0006050.ref020],[@pntd.0006050.ref022],[@pntd.0006050.ref024]--[@pntd.0006050.ref027]\]. Thus, it is important to examine the range of *Wolbachia*-induced phenotypes so that efficacy of disease control efforts using *Wolbachia*-induced pathogen interference are not impeded.

Previous work has demonstrated that somatic *Wolbachia* (strain *w*AlbB) infections in *Culex tarsalis* (Yolo strain) enhanced West Nile virus (WNV) infection rates \[[@pntd.0006050.ref024]\]. To better understand the range of *Wolbachia*-induced phenotypes, we investigated the effects of *w*AlbB on Rift Valley fever virus (RVFV) infection in *Cx*. *tarsalis*. RVFV is a member of the genus *Phlebovirus* in the family Bunyaviridae and predominately affects domestic ruminants, causing severe economic losses in the livestock industry and human morbidity in Africa and the Middle East \[[@pntd.0006050.ref028]--[@pntd.0006050.ref030]\]. Additionally, models and laboratory studies have suggested the United States may have environmental conditions and mosquito vectors that would permit RVFV introduction and invasion \[[@pntd.0006050.ref031]--[@pntd.0006050.ref034]\]. *Cx*. *tarsalis* are abundant in the western U.S. and are highly competent laboratory vectors for RVFV \[[@pntd.0006050.ref033]--[@pntd.0006050.ref035]\]. We assessed the ability of *Wolbachia* to affect RVFV infection, dissemination, and transmission within *Cx*. *tarsalis* at two time points and evaluated relationships between viral titer and *Wolbachia* density in mosquitoes.

Materials and methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

Mosquitoes were maintained on commercially obtained anonymous human blood using a membrane feeder (Biological Specialty Corporation, Colmar, PA). RVFV experiments were performed under biosafety-level 3 (BSL-3) and arthropod-containment level 3 (ACL3) conditions.

Research at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) was conducted under an Institutional Animal Care and Use Committee (IACUC) approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conducted is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and adheres to the principles stated in the *Guide for the Care and Use of Laboratory Animals*, National Research Council, 2011. The USAMRIID IACUC specifically approved this study.

Mosquitoes and *Wolbachia* {#sec004}
--------------------------

The *Culex tarsalis* colony used for all experiments was derived from field mosquitoes collected in Yolo County, CA in 2009. Mosquitoes were reared and maintained at 27°C ± 1°C, 12:12 hr light:dark diurnal cycle at 80% relative humidity in 30×30×30 cm cages. The *w*AlbB *Wolbachia* strain was purified from *An*. *gambiae* Sua5B cells according to published protocols \[[@pntd.0006050.ref036]\]. *Wolbachia* viability and density was assessed using the LIVE/DEAD BacLight Bacterial Viability Kit (Invitrogen, Carlsbad, CA) and a hemocytometer. The RVFV vector competence experiment was replicated three times with different hamsters, and *w*AlbB concentrations for those replicates as follows: replicate one, 2.5 × 10^9^ bacteria/ml; replicate two, 2.5 × 10^9^ bacteria/ml; replicate three, 5.0 × 10^9^ bacteria/ml.

Two- to 4-day-old adult female *Cx*. *tarsalis* were anesthetized with CO~2~ and intrathoracically injected with approximately 0.1 μl of either suspended *w*AlbB or Schneider's insect media (Sigma Aldrich, Saint Louis, MO) as a control. Mosquitoes were provided with 10% sucrose *ad libitum* and maintained at 27°C in a growth chamber.

Vector competence for RVFV {#sec005}
--------------------------

RVFV strain ZH501 was isolated from the blood of a fatal human case in Egypt in 1977 \[[@pntd.0006050.ref037]\]. Adult female Syrian hamsters were inoculated intraperitoneally with 0.2 ml of a suspension containing RVFV in diluent (10% heat-inactivated fetal bovine serum in Medium 199 with Earle's salts \[Invitrogen\], sodium bicarbonate, and antibiotics) containing approximately 10^5^ plaque-forming units (PFU) per ml of RVFV. Approximately 28--30 hr post-inoculation, infected hamsters were anesthetized with a suspension of ketamine, acepromazine, and xylazine. A single viremic hamster was placed across two 3.8-liter cardboard cages containing either *Wolbachia*-infected *Cx*. *tarsalis* or control-injected *Cx*. *tarsalis*, treatments to which the experimenter was blinded. Mosquitoes were allowed to feed for one hour. After this period, hamsters were removed, a blood sample taken to determine viremia, and hamsters were euthanized.

After feeding, mosquitoes were anesthetized with CO~2~ and examined for feeding status; partially or non-blood fed females were discarded. For all replicates, one blood fed mosquito from each treatment was sampled to test for input viral titers. Mosquitoes were sampled at 7 and 14 days post-blood feeding. On day 7, mosquitoes were anesthetized with CO~2~ and had their legs removed; each set of legs was placed into one 2-ml microcentrifuge tube containing 1 ml of mosquito diluent (20% heat-inactivated fetal bovine serum \[FBS\] in Dulbecco's phosphate-buffered saline, 50 μg/ml penicillin streptomycin, and 2.5 μg/ml fungizone). Bodies were placed separately into 2-ml microcentrifuge tubes (Eppendorf, Hauppauge, NY) containing 1 ml of mosquito diluent. On day 14, bodies and legs were collected in the same manner as day 7, except that prior to placing bodies into microcentrifuge tubes, saliva was collected from mosquitoes by positioning the proboscis of each mosquito into a capillary tube containing approximately 10 μl of a 1:1 solution of 50% sucrose and FBS. After 30 minutes, the contents were expelled in individual microcentrifuge tubes containing 0.3 ml of mosquito diluent. A 5 mm stainless steel bead (Qiagen, Valencia, CA) was placed into all microcentrifuge tubes that contained mosquito bodies and legs, homogenized in a mixer mill (Retsch, Haan, Germany) for 30 seconds at 24 cycles per second, and centrifuged for 1 minute at 8000 rpm. All mosquito bodies, legs, and saliva were stored at -80°C until assayed.

Samples were tested for RVFV infectious particles by plaque assay on Vero cells according to previous published protocols \[[@pntd.0006050.ref038]\]. Serial dilutions were prepared for all mosquito body, leg, and saliva samples. One hundred microliters of each dilution was inoculated onto Vero cell culture monolayers. Inoculated plates were incubated at 37°C for 1 hr and an agar overlay was added (1X EBME, 0.75% agarose, 7% FBS, 1% penicillin streptomycin, and 1% nystatin). Plates were incubated at 37°C for 3 days and then a second overlay (1X EBME, 0.75% agarose, and 4% neutral red) was added. Plaques were counted 24 hr after application of the second overlay and titers calculated.

Quantitative real-time PCR of *Wolbachia* density {#sec006}
-------------------------------------------------

To evaluate relationships between *Wolbachia* density and RVFV titer, we measured *w*AlbB levels in individual mosquitoes. DNA was extracted from 200 μl of mosquito body homogenate using the DNeasy blood and tissue kit (Qiagen) and used as template for qPCR on a Rotor-Gene Q (Qiagen) with the PerfeCta SYBR FastMix kit (Quanta Biosciences, Beverly, MA) or on ABI 7500 with Power SYBR green master mix (Applied Biosystems, Foster City, CA). The qPCR assays were performed in 10μl reactions and amplification was carried out using a standardized program at 95°C for 5 min, 40 cycles of 95°C for 10 sec, 60°C for 15 sec, and 72°C for 10 sec. *Wolbachia* DNA was amplified with primers Alb-GF and Alb-GR \[[@pntd.0006050.ref039]\] and was normalized to the *Cx*. *tarsalis* actin gene by using qGene software \[[@pntd.0006050.ref024],[@pntd.0006050.ref040]\]. qPCRs were performed in duplicate.

Statistical analyses {#sec007}
--------------------

Infection, dissemination, and transmission rates were compared between *Wolbachia*-infected and control *Cx*. *tarsalis*, and between replicates with Fisher's exact tests. Due to violations of assumptions needed for parametric tests, Mann-Whitney U was used to compare the following data sets: RVFV body titers between *Wolbachia*-infected and control mosquitoes, RVFV body titers between RVFV-positive saliva and RVFV-negative saliva, RVFV body titers over time, and *Wolbachia* density over time. Unpaired t-tests were used to analyze data that passed normality tests, including the comparison of RVFV saliva titers between *Wolbachia*-infected and control mosquitoes. To determine relationships between *Wolbachia* density and RVFV body titer, the Spearman rank correlation test was used, as assumptions for Pearson correlation were violated. All statistical analyses were performed in GraphPad Prism version 7 for Windows (GraphPad Software, San Diego, CA).

Results {#sec008}
=======

Vector competence for RVFV {#sec009}
--------------------------

After all hamster feeds (i.e., replicates), one blood fed mosquito from each treatment was tested for input RVFV titers on the day of blood feeding. These day 0 RVFV titer results for *Wolbachia*-infected *Cx*. *tarsalis* were as follows: replicate 1, 2.50 × 10^2^ PFU/ml; replicate 2, 7.00 × 10^6^ PFU/ml; replicate 3, 1.00 × 10^2^ PFU/ml. Day 0 results for control *Cx*. *tarsalis* were as follows: replicate 1, 5.00 × 10^2^ PFU/ml; replicate 2, 1.05 × 10^7^ PFU/ml; replicate 3, 1.00 ×10^2^ PFU/ml. Viremias in the three hamsters were 10^4^, 10^9^, and 10^3^ PFU/ml, respectively.

To determine RVFV vector competence of *Wolbachia*-infected and *Wolbachia*-uninfected *Cx*. *tarsalis*, we examined frequencies of RVFV-positive bodies ([Fig 1A](#pntd.0006050.g001){ref-type="fig"}), legs ([Fig 1B](#pntd.0006050.g001){ref-type="fig"}), and saliva ([Fig 1C](#pntd.0006050.g001){ref-type="fig"}). Infection rate is the proportion of mosquito bodies that contained infectious RVFV. Dissemination and transmission rates are the proportion of infected mosquitoes with RVFV positive legs and saliva, respectively. Three replicate experiments were performed, and individual data from those experiments are available in [S1 Table](#pntd.0006050.s001){ref-type="supplementary-material"}. Hamster viremia in replicate three was low and resulted in low mosquito infection rates. Replicate two infection frequencies were significantly higher than replicate one for both treatments and at both day 7 and day 14 (P \< 0.0001) ([S1 Table](#pntd.0006050.s001){ref-type="supplementary-material"}). However, [Fig 1](#pntd.0006050.g001){ref-type="fig"} and [S1 Table](#pntd.0006050.s001){ref-type="supplementary-material"} show that across replicates and time points, *Wolbachia*-infected *Cx*. *tarsalis* infection, dissemination, and transmission rates did not differ significantly from *Wolbachia*-uninfected *Cx*. *tarsalis*. Thus, the data were pooled for further analysis.

![Effects of *Wolbachia* infection on RVFV vector competence frequencies in *Cx*. *tarsalis*.\
RVFV infection 7 and 14 days post-feeding (A), dissemination 7 and 14 days post-feeding (B), and transmission rates 14 days post-feeding (C) were compared between *Wolbachia*-infected and control *Cx*. *tarsalis*. Bars represent data pooled from three replicates. Error bars denote binomial confidence intervals. See [S1 Table](#pntd.0006050.s001){ref-type="supplementary-material"} for replicate-specific analyses.](pntd.0006050.g001){#pntd.0006050.g001}

RVFV body ([Fig 2A](#pntd.0006050.g002){ref-type="fig"}) and saliva titers ([Fig 2B](#pntd.0006050.g002){ref-type="fig"}) were determined for *Wolbachia*-infected and control *Cx*. *tarsalis*. There were no significant differences in RVFV body titer or saliva titer between *Wolbachia*-infected and control *Cx*. *tarsalis* at either day 7 ([Fig 2A](#pntd.0006050.g002){ref-type="fig"}) or day 14 ([Fig 2B](#pntd.0006050.g002){ref-type="fig"}). Additionally, when replicate data were pooled, both *Wolbachia*-infected and uninfected *Cx*. *tarsalis* that had higher RVFV body titers were more likely to have RVFV-positive saliva ([S1 Fig](#pntd.0006050.s003){ref-type="supplementary-material"}).

![Comparison of RVFV body and saliva titers between *Wolbachia*-infected and control *Cx*. *tarsalis*.\
At both 7 and 14 days post-blood meal, there were no significant differences in RVFV body titers (A) or saliva titers (B) of *Wolbachia*-infected *Cx*. *tarsalis* compared to control *Cx*. *tarsalis*. All replicates are combined in this figure; separate replicates are provided in supplementary materials ([S2 Fig](#pntd.0006050.s004){ref-type="supplementary-material"}). Bars represent medians and bolded numbers above the data points denote sample sizes.](pntd.0006050.g002){#pntd.0006050.g002}

Quantitative real-time PCR of *Wolbachia* (*w*AlbB) density {#sec010}
-----------------------------------------------------------

We performed qPCR from the DNA of each mosquito and determined *Wolbachia* density as an expression normalized to a reference gene, actin \[[@pntd.0006050.ref040]\]. We used all samples that were positive for *Wolbachia* to analyze relationships between *Wolbachia* density and RVFV body titer; we combined data from all replicate experiments ([Fig 3](#pntd.0006050.g003){ref-type="fig"}). Overall, there was a moderate, negative correlation between *Wolbachia* density and RVFV body titer at both day 7 and 14 ([Fig 3A and 3B](#pntd.0006050.g003){ref-type="fig"}). Replicate two, the replicate with the highest infection rates, did not have significant correlations between *Wolbachia* density and RVFV body titer at either day 7 (*n* = 14, r = 0.0516, p = 0.062) or day 14 (*n* = 27, r = 0.112, p = 0.577) (raw data available [S2 Table](#pntd.0006050.s002){ref-type="supplementary-material"}). *Wolbachia* density was also compared across time; *Wolbachia* concentration at day 14 was significantly higher than at day 7, consistent with *Wolbachia* replication in mosquitoes ([S3 Fig](#pntd.0006050.s005){ref-type="supplementary-material"}).

![Correlation between RVFV body titer and *Wolbachia* levels in *Cx*. *tarsalis*.\
*Wolbachia* levels were normalized to the host gene actin. Normalized *Wolbachia* levels and RVFV body titer for each mosquito were plotted and analyzed with the Spearman rank correlation test to determine relationships. There was a moderate, negative correlation between RVFV body titer and *Wolbachia* levels at both day 7 (*n* = 46) (A) and day 14 (n = 54) (B) post-blood feeding (Fig 3). Data for all replicates were combined; see [S2 Table](#pntd.0006050.s002){ref-type="supplementary-material"} for replicate-specific raw data.](pntd.0006050.g003){#pntd.0006050.g003}

Discussion {#sec011}
==========

*Wolbachia* infection can have varied effects on viruses and parasites transmitted by mosquitoes. These effects can include moderate to complete pathogen inhibition, as well as pathogen enhancement \[[@pntd.0006050.ref017],[@pntd.0006050.ref022],[@pntd.0006050.ref024],[@pntd.0006050.ref041],[@pntd.0006050.ref042]\]. In a previous study, we found that *Wolbachia* strain *w*AlbB enhanced WNV infection frequency in *Cx*. *tarsalis* \[[@pntd.0006050.ref024]\], although in that study, viral infection titers were not measured. To understand how widespread the *Wolbachia*-induced enhancement phenotype is in *Cx*. *tarsalis*, we studied *w*AlbB effects on RVFV, an important arthropod-borne virus with potential to invade the United States \[[@pntd.0006050.ref043],[@pntd.0006050.ref044]\]. In contrast to our previous results, we found that *w*AlbB did not affect RVFV body or saliva titers, nor RVFV infection, dissemination, or transmission frequencies in *Cx*. *tarsalis*.

*Wolbachia*-mediated effects on pathogens may depend on *Wolbachia* density. Several studies have reported that high densities of *Wolbachia* are more likely than low densities to block viruses in *Drosophila* spp. and mosquitoes \[[@pntd.0006050.ref045]--[@pntd.0006050.ref048]\]. Similarly, we found a moderate, negative correlation between RVFV body titer and *Wolbachia* density. High *Wolbachia* levels were associated with RVFV negative mosquitoes or those with low RVFV body titers. The low numbers of mosquitoes at the high *Wolbachia* densities may explain why we did not see a *Wolbachia* effect on population level vector competence measures. However, our correlation data suggests that in this system, *Wolbachia* may suppress RVFV in a density-dependent manner.

In this *Cx*. *tarsalis*-*w*AlbB system, we have reported different effects of *Wolbachia* on vector competence for WNV and RVFV \[[@pntd.0006050.ref024]\]. Other studies have found similar differences in *Wolbachia* phenotypes and suggested they may depend on various factors including environmental conditions, and pathogen type \[[@pntd.0006050.ref020],[@pntd.0006050.ref049]\]. RVFV and WNV belong to different virus families and could interact with the mosquito host environment and *Wolbachia* in different ways. For example, a recent study suggested that the mosquito JAK/STAT pathway may not have the same antiviral effects on closely related viruses \[[@pntd.0006050.ref050]\]. Although the mosquitoes in our two studies have the same genetic background, they were reared in separate facilities and may have different microbiomes that may explain differences in vector competence \[[@pntd.0006050.ref051]\].

While artificial feeding methods such as membrane feeders or pledgets allow one to easily standardize viral titers, previous studies on mosquito RVFV and other virus infections demonstrated significantly reduced mosquito infectivity using an artificial feeding system compared to a live infected animal \[[@pntd.0006050.ref052], [@pntd.0006050.ref053]\]. We therefore decided to use live hamsters infected with a highly virulent and epidemiologically relevant viral strain in our experiments. However, this more biologically relevant choice comes with a trade-off; it is impossible to standardize the viral titer in a live animal infection model. While all hamsters were infected with approximately the same amount of virus, they varied in their response to the infection, resulting in significant variation in final viral blood titers across experimental replicates that reduced statistical power.

Our study was performed with an adult microinjection model that generates mosquitoes transiently infected with *Wolbachia*. It remains to be seen whether this model reflects relationships between *Wolbachia* and viruses in *Cx*. *tarsalis* in a stable infection system. However, a recent study showed that both stable and transient *w*AlbB infections in *Ae*. *aegypti* produced similar results \[[@pntd.0006050.ref045]\]. This suggests that our transient infection model may correlate with a stable infection in *Cx*. *tarsalis*.

Despite relatively modest measurable effects in these experiments, our results underscore the necessity of studying diverse *Wolbachia*-host-pathogen systems. It is becoming increasingly clear that one cannot extrapolate results of one system of interactions across all systems; every *Wolbachia*-host-pathogen system must be individually examined. Future studies should seek to understand the mechanisms underlying variation of *Wolbachia* protective effects across diverse mosquito species, viral/pathogen species, and *Wolbachia* strains.

Supporting information {#sec012}
======================

###### Vector competence of *Cx*. *tarsalis* following a RVFV blood meal.

RVFV infection, dissemination, and transmission frequencies were compared between *Wolbachia*-infected and control mosquitoes. Replicates are displayed individually.

(XLSX)

###### 

Click here for additional data file.

###### Raw data for manuscript.

(XLSX)

###### 

Click here for additional data file.

###### Comparison of RVFV body titers in *Cx*. *tarsalis* with virus present or absent in the saliva.

RVFV body titers were compared between mosquitoes that tested positive or negative for RVFV in their saliva. For both *Wolbachia-*infected and control *Cx*. *tarsalis*, mosquitoes positive for RVFV in the saliva had significantly higher RVFV body titers compared to mosquitoes negative for virus in the saliva There was no significant difference in RVFV body titer of transmitters between *Wolbachia*-infected and control mosquitoes (*p* = 0.7692). Data from three replicates were pooled and analyzed with Mann-Whitney U, and the bars represent medians.

(TIF)

###### 

Click here for additional data file.

###### Comparison of RVFV body titers between treatments by replicate.

RVFV body titers were compared between *Wolbachia*-infected and control mosquitoes for replicates 1 (A), 2 (B), and 3 (C). In all replicates, there were no significant differences in RVFV body titer between *Wolbachia*-infected and control mosquitoes. Data did not pass assumptions for normality and were analyzed with Mann-Whitney U, and sample sizes are denoted above data points.

(TIF)

###### 

Click here for additional data file.

###### *Wolbachia* density over time.

*Wolbachia* levels for each mosquito, determined by qPCR, were combined across all three replicates. *Wolbachia* levels were significantly higher at day 14 compared to day 7. Due to violations of normality, Mann-Whitney U was used for comparisons, bars are medians, and numbers above data points are sample sizes.

(TIF)

###### 

Click here for additional data file.
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